Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume -, Issue -, Pages ASN.2020050723
Publisher
American Society of Nephrology (ASN)
Online
2020-10-01
DOI
10.1681/asn.2020050723
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
- (2019) Josef Coresh et al. Lancet Diabetes & Endocrinology
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Change in albuminuria as a surrogate endpoint in chronic kidney disease – Authors' reply
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- The new biology of diabetic kidney disease - mechanisms and therapeutic implications
- (2019) Yuliya Lytvyn et al. ENDOCRINE REVIEWS
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
- (2019) JingWei Li et al. JACC-Heart Failure
- Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
- (2018) Hiddo J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD
- (2018) Sophie M. van den Belt et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics
- (2018) Susanne Eder et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus
- (2018) Toshiaki Ohkuma et al. HYPERTENSION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Is a reduction in albuminuria associated with renal and cardiovascular protection? Apost hocanalysis of the ALTITUDE trial
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
- (2010) Andrew S. Levey et al. KIDNEY INTERNATIONAL
- “Proportion Explained”: A Causal Interpretation for Standard Measures of Indirect Effect?
- (2009) Danella M. Hafeman AMERICAN JOURNAL OF EPIDEMIOLOGY
- First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria
- (2008) E. C. Witte et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation